| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_40765ca9a78b54a8a76f781d159ad145 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-522
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-16 |
| filingDate |
2012-12-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_439e8ea035b97e510d4901c3f6ef6bfd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a79bbbafee557675b5bceb091f10ad6c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_80cddd8d85f99bdf27d4f6ae0048f500 |
| publicationDate |
2013-01-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
AU-2012261721-A1 |
| titleOfInvention |
Method of preventing and treating hepatic disease using A2B adenosine receptor antagonists |
| abstract |
The invention is related to methods of preventing and treating hepatic fibrosis using A2B adenosine receptor antagonists and utility in the treatment and prevention of liver damage caused by alcohol abuse, surgical intervention, viral hepatitis, the ingestion of hepatotoxic drugs, or other 5 hepatic diseases. The invention also relates to pharmaceutical compositions for use in the method. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11116737-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023274352-A1 |
| priorityDate |
2006-03-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |